Literature DB >> 11165138

Heterogeneous lack of expression of the tumour suppressor PTEN protein in human neoplastic tissues.

J Torres1, S Navarro, I Roglá, F Ripoll, A Lluch, J García-Conde, A Llombart-Bosch, J Cervera, R Pulido.   

Abstract

PTEN, a tumour suppressor gene located at chromosome 10q23 and commonly mutated or deleted in a variety of tumours, encodes a dual-specific/phosphatidylinositol-3,4,5-triphosphate (PIP3) phosphatase. We report the generation of an anti-PTEN monoclonal antibody (MAb) that recognises an epitope at the C-terminus of PTEN, and describe the heterogeneous lack of expression of the PTEN protein in human tumour tissues, as demonstrated by immunohistochemical methods. Our anti-PTEN MAb provides a useful tool for the study of PTEN protein expression in tumour samples, in the search for tumour prognostic molecular markers.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11165138     DOI: 10.1016/s0959-8049(00)00366-x

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  10 in total

1.  PTEN recruitment controls synaptic and cognitive function in Alzheimer's models.

Authors:  Shira Knafo; Cristina Sánchez-Puelles; Ernest Palomer; Igotz Delgado; Jonathan E Draffin; Janire Mingo; Tina Wahle; Kanwardeep Kaleka; Liping Mou; Inmaculada Pereda-Perez; Edvin Klosi; Erik B Faber; Heidi M Chapman; Laura Lozano-Montes; Ana Ortega-Molina; Lara Ordóñez-Gutiérrez; Francisco Wandosell; Jose Viña; Carlos G Dotti; Randy A Hall; Rafael Pulido; Nashaat Z Gerges; Andrew M Chan; Mark R Spaller; Manuel Serrano; César Venero; José A Esteban
Journal:  Nat Neurosci       Date:  2016-01-18       Impact factor: 24.884

2.  Nuclear localization of PTEN by a Ran-dependent mechanism enhances apoptosis: Involvement of an N-terminal nuclear localization domain and multiple nuclear exclusion motifs.

Authors:  Anabel Gil; Amparo Andrés-Pons; Elena Fernández; Miguel Valiente; Josema Torres; Javier Cervera; Rafael Pulido
Journal:  Mol Biol Cell       Date:  2006-06-28       Impact factor: 4.138

3.  Heterogeneous Expression and Subcellular Localization of Pyruvate Dehydrogenase Complex in Prostate Cancer.

Authors:  Caroline E Nunes-Xavier; Janire Mingo; Maite Emaldi; Karine Flem-Karlsen; Gunhild M Mælandsmo; Øystein Fodstad; Roberto Llarena; José I López; Rafael Pulido
Journal:  Front Oncol       Date:  2022-05-25       Impact factor: 5.738

4.  Akt phosphorylation and nuclear phosphoinositide association mediate mRNA export and cell proliferation activities by ALY.

Authors:  Masashi Okada; Sang-Wuk Jang; Keqiang Ye
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-17       Impact factor: 11.205

5.  Predictive value of PTEN and AR coexpression of sustained responsiveness to hormonal therapy in prostate cancer--a pilot study.

Authors:  Soha Salama El Sheikh; Hanna M Romanska; Paul Abel; Jan Domin; El-Nasir Lalani
Journal:  Neoplasia       Date:  2008-09       Impact factor: 5.715

6.  Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients.

Authors:  Zacharenia Saridaki; Maria Tzardi; Chara Papadaki; Maria Sfakianaki; Fraga Pega; Aristea Kalikaki; Eleftheria Tsakalaki; Maria Trypaki; Ippokratis Messaritakis; Efstathios Stathopoulos; Dimitris Mavroudis; Vassilis Georgoulias; John Souglakos
Journal:  PLoS One       Date:  2011-01-20       Impact factor: 3.240

7.  PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib.

Authors:  Leiping Wang; Qunling Zhang; Jian Zhang; Si Sun; Haiyi Guo; Zhen Jia; Biyun Wang; Zhimin Shao; Zhonghua Wang; Xichun Hu
Journal:  BMC Cancer       Date:  2011-06-15       Impact factor: 4.430

8.  Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS.

Authors:  Tomokazu Kishiki; Hiroaki Ohnishi; Tadahiko Masaki; Kouki Ohtsuka; Yasuo Ohkura; Jyunji Furuse; Takashi Watanabe; Masanori Sugiyama
Journal:  Cancer Chemother Pharmacol       Date:  2014-02-06       Impact factor: 3.333

9.  MiR-486 regulates lactation and targets the PTEN gene in cow mammary glands.

Authors:  Dan Li; Xuejiao Xie; Jie Wang; Yanjie Bian; Qingzhang Li; Xuejun Gao; Chunmei Wang
Journal:  PLoS One       Date:  2015-03-04       Impact factor: 3.240

10.  Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.

Authors:  D Tural; S Serdengecti; F Demirelli; T Öztürk; S İlvan; H Turna; M Özgüroglu; E Büyükünal
Journal:  Br J Cancer       Date:  2014-03-04       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.